Selected article for: "Nipah virus and West Nile virus"
Author: Michelow, Ian C.; Lear, Calli; Scully, Corinne; Prugar, Laura I.; Longley, Clifford B.; Yantosca, L. Michael; Ji, Xin; Karpel, Marshall; Brudner, Matthew; Takahashi, Kazue; Spear, Gregory T.; Ezekowitz, R. Alan B.; Schmidt, Emmett V.; Olinger, Gene G.
Title: High-Dose Mannose-Binding Lectin Therapy for Ebola Virus Infection
  • Document date: 2011_1_15
    • ID: jvs25q21_15
    Snippet: In the past 3 decades, approved antivirals have increased from a few nucleoside analogues to well over 40 drugs [13] . The human immunodeficiency virus (HIV) and hepatitis C virus (HCV) epidemics particularly drove antiviral discovery toward rationally designed drugs targeting specific viral enzymes. Although this approach was remarkably effective, the advent of newly emerging or drug-resistant viruses that threaten humans calls for the developme.....
    Document: In the past 3 decades, approved antivirals have increased from a few nucleoside analogues to well over 40 drugs [13] . The human immunodeficiency virus (HIV) and hepatitis C virus (HCV) epidemics particularly drove antiviral discovery toward rationally designed drugs targeting specific viral enzymes. Although this approach was remarkably effective, the advent of newly emerging or drug-resistant viruses that threaten humans calls for the development of more broadly active agents targeting viral components shared among viruses. N-glycosylation of viral envelopes is an important such target shared between influenza, HIV, HCV, West Nile virus, SARS-CoV, Hendra virus, Nipah virus, and filoviruses (Ebola and Marburg viruses) [7] . To assess one possible strategy against N-glycosylated viruses, we tested a stringent Ebola virus infection model (3000 3 LD 50 ) in mice.

    Search related documents:
    Co phrase search for related documents
    • antiviral discovery and HIV human immunodeficiency virus: 1, 2, 3, 4
    • antiviral discovery and human immunodeficiency: 1, 2, 3, 4, 5, 6, 7
    • antiviral discovery and human immunodeficiency virus: 1, 2, 3, 4, 5, 6, 7
    • antiviral discovery and infection model: 1
    • antiviral discovery and nucleoside analogue: 1
    • antiviral discovery and possible strategy: 1
    • antiviral discovery and viral component: 1, 2
    • antiviral discovery and viral envelope: 1
    • antiviral discovery and viral enzyme: 1, 2, 3
    • antiviral discovery and West Nile virus: 1, 2, 3